Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963927 | 0.85 | CNR2 (0.70) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964322 | 0.84 | CNR2 (0.68) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5963869 | 0.84 | CNR2 (1.00) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5963872 | 0.84 | CNR2 (1.00) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964304 | 0.84 | CNR2 (1.00) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964583 | 0.82 | CNR2 (0.65) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL13993320 | 0.81 | KDM4E (0.70) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL14274010 | 0.81 | KDM4E (0.70) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL28339091 | 0.81 | KDM4E (0.70) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964325 | 0.81 | CNR2 (0.64) | CNR2KDM4ESMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | CNR2 2/4885KDM4E 3936/4885SMN1; SMN2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.